bioMérieux: Invest Securities neutral, raises target price

(CercleFinance.com) - While reiterating its "neutral" rating on the bioMérieux share, Invest Securities has raised its target price from 104 euros to 115 euros, following the in vitro diagnostics specialist's announcement of much better than expected growth in the second quarter.


This succinct publication highlighted the initial effects of the crisis, with a decline in the immuno assays and microbiology divisions, which was more than offset by molecular biology, the analyst said.

Following this publication, the research department significantly raised its expectations for the group over 2020 (EPS estimate +21%), although there is no major impact on its estimated EPS for 2021 and 2022 (+3.2% and +1.5% respectively).


Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.